Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03217136 · ClinicalTrials.gov registry record · Phase 2
MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)
A Phase 2 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 2
- Development phase
- 94
- Enrollment target
NCT03217136 is a Phase 2 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 94 participants.
The verdict
NCT03217136, a Phase 2 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 94 participants
- Enrollment target
Study Summary
This study aims to evaluate the safety and tolerability of MK-7625A (ceftolozane/tazobactam) plus metronidazole, compared with that of meropenem in pediatric participants with cIAI.
Interventions
- DRUG Metronidazole
- DRUG Meropenem
- DRUG Ceftolozane/Tazobactam
- DRUG Placebo for Metronidazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2018-04-03 |
| Est. Completion | 2020-03-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03217136
The ClinicalTrials.gov registry entry for NCT03217136 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Metronidazole is the first listed.
NCT03217136 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03217136 about?
NCT03217136 is a clinical study titled "MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)". This study aims to evaluate the safety and tolerability of MK-7625A (ceftolozane/tazobactam) plus metronidazole, compared with that of meropenem in pediatric participants with cIAI.
What is the current status of trial NCT03217136?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 94 participants. The study started on 2018-04-03. Estimated completion is 2020-03-16.
What interventions are being tested in trial NCT03217136?
The interventions under investigation include: Metronidazole (DRUG), Meropenem (DRUG), Ceftolozane/Tazobactam (DRUG), Placebo for Metronidazole (DRUG).
Who is sponsoring clinical trial NCT03217136?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.